Resona Asset Management Co. Ltd. Sells 21,761 Shares of Bristol Myers Squibb Company $BMY

Posted by Brian Himes on May 19th, 2026

Resona Asset Management Co. Ltd. lowered its position in Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 3.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 669,366 shares of the biopharmaceutical company’s stock after selling 21,761 shares during the period. Resona Asset Management Co. Ltd.’s holdings in Bristol Myers Squibb were worth $36,125,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. waypoint wealth counsel bought a new position in Bristol Myers Squibb during the 4th quarter worth about $1,194,000. Phoenix Financial Ltd. increased its holdings in Bristol Myers Squibb by 110.1% during the 3rd quarter. Phoenix Financial Ltd. now owns 106,154 shares of the biopharmaceutical company’s stock worth $4,789,000 after purchasing an additional 55,624 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in Bristol Myers Squibb by 4.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,211,845 shares of the biopharmaceutical company’s stock worth $99,754,000 after purchasing an additional 93,528 shares in the last quarter. Oppenheimer Asset Management Inc. increased its holdings in Bristol Myers Squibb by 6.4% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 531,538 shares of the biopharmaceutical company’s stock worth $23,972,000 after purchasing an additional 32,005 shares in the last quarter. Finally, M&G PLC increased its holdings in Bristol Myers Squibb by 1.4% during the 3rd quarter. M&G PLC now owns 6,885,188 shares of the biopharmaceutical company’s stock worth $309,833,000 after purchasing an additional 97,063 shares in the last quarter. Institutional investors own 76.41% of the company’s stock.

Insider Transactions at Bristol Myers Squibb

In related news, EVP David V. Elkins sold 30,000 shares of the firm’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total value of $1,850,100.00. Following the completion of the sale, the executive vice president directly owned 159,248 shares in the company, valued at approximately $9,820,824.16. This trade represents a 15.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 0.05% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. HSBC increased their target price on Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a report on Tuesday, March 17th. Barclays assumed coverage on Bristol Myers Squibb in a report on Thursday, February 19th. They set an “overweight” rating and a $75.00 target price for the company. Royal Bank Of Canada assumed coverage on Bristol Myers Squibb in a report on Tuesday, February 24th. They set a “sector perform” rating and a $60.00 target price for the company. Citigroup restated a “neutral” rating on shares of Bristol Myers Squibb in a report on Friday, May 1st. Finally, Morgan Stanley restated an “underweight” rating and issued a $40.00 price objective on shares of Bristol Myers Squibb in a report on Friday, February 6th. Eight analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Bristol Myers Squibb presently has an average rating of “Hold” and a consensus price target of $61.31.

Check Out Our Latest Stock Analysis on BMY

Bristol Myers Squibb Price Performance

Shares of NYSE BMY opened at $57.30 on Tuesday. The stock has a market capitalization of $117.02 billion, a price-to-earnings ratio of 16.10, a PEG ratio of 0.16 and a beta of 0.26. The business has a 50-day moving average of $58.57 and a 200-day moving average of $55.53. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.42 and a quick ratio of 1.28. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $62.89.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $1.42 by $0.16. The company had revenue of $11.49 billion during the quarter, compared to analysts’ expectations of $10.93 billion. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.Bristol Myers Squibb’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter last year, the company earned $1.80 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, sell-side analysts predict that Bristol Myers Squibb Company will post 6.31 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, May 1st. Investors of record on Thursday, April 2nd were paid a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 4.4%. The ex-dividend date was Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is 70.79%.

Bristol Myers Squibb Profile

(Free Report)

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.